FOLFOXIRI FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: A population-based cohort study.

Date publication

mars 2020

Journal

World journal of gastrointestinal oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BORG Christophe , Dr FEIN Francine , Dr VERNEREY Dewi , Dr VIENOT Angélique , Dr KIM Stephano , Mme MEURISSE Aurélia

Tous les auteurs :
Vienot A, Chevalier H, Bolognini C, Gherga E, Klajer E, Meurisse A, Jary M, Kim S, d'Engremont C, Nguyen T, Calcagno F, Almotlak H, Fein F, Nasri M, Abdeljaoued S, Turpin A, Borg C, Vernerey D

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/32206183

Résumé

FOLFIRINOX regimen is the first-line reference chemotherapy (L1) in advanced pancreatic ductal adenocarcinoma (aPDAC). FOLFOXIRI, a schedule with a lower dose of irinotecan and no bolus 5-fluorouracil, has demonstrated efficacy and feasibility in colorectal cancer.

Mots clés

Advanced pancreatic cancer, Cohort study, FOLFIRINOX, FOLFOXIRI, First-line chemotherapy, Propensity score

Référence

World J Gastrointest Oncol. 2020 Mar 15;12(3):332-346